文献速递产科母胎医学

产前阴道黄体酮预防早产与双绒毛膜双胎6至9岁时精神病理及认知特征无关联:一项随机对照试验的随访研究

Prenatal exposure to vaginal progesterone for the prevention of preterm birth is not associated with abnormal psychopathological and cognitive profiles in dichorionic twins at 6 to 9 years of age: a follow-up study of a randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2025-06-05

本研究为一项多中心、双盲、随机对照试验的随访研究,评估产前每日使用阴道黄体酮200 mg或400 mg预防早产的产妇所生双绒毛膜双胎在6至9岁时的精神病理和认知特征。共纳入104名母亲的206名儿童,结果显示各黄体酮组与安慰剂组在儿童行为量表11项综合征量表均分及总分组间均无显著差异,瑞文测验百分位亦无显著差异。

要点

  • 阴道黄体酮200 mg/d、400 mg/d或两剂量合并暴露组与安慰剂组在儿童行为量表11项综合征量表均分上均无显著差异(所有P值≥.05)。
  • 儿童行为量表总分组间无显著差异:200 mg/d组31.08±22.58、400 mg/d组37.48±28.59、两剂量组合组34.00±25.60、安慰剂组34.60±25.55(P分别为.38、.54、.87)。
  • 瑞文测验平均百分位在200 mg/d组(63.11±27.03)和400 mg/d组(60.40±31.51)略高于安慰剂组(59.40±30.64),但差异未达统计学显著(P分别为.44、.85)。

核心结论

  • 妊娠后半期每日使用200 mg或400 mg阴道黄体酮预防早产,对双绒毛膜双胎6至9岁时精神病理及认知特征无影响。

研究设计与样本

  • 本研究为一项多中心、双盲、随机对照试验(3个平行组:安慰剂、阴道黄体酮200 mg/d、阴道黄体酮400 mg/d,于妊娠20至34周或分娩时停药,以先发生者为准;随机分配比1:1:1)的随访研究。
  • 共纳入104名母亲的206名儿童(占原随机对照试验纳入者的35.4%):阴道黄体酮200 mg/d暴露75名、400 mg/d暴露63名、安慰剂暴露68名。
  • 采用儿童行为量表6至18岁版问卷和瑞文彩色推理测验分别评估参与母亲及其存活子女(6至9岁);参与母亲、问卷收集者和数据库管理者对原试验干预分组设盲。
  • 主要结局为儿童行为量表6至18岁版问卷评估的行为、情绪和社会问题,以及瑞文彩色推理测验评估的智力系数百分位;按意向性治疗原则分析,P值<.05视为有统计学意义。

主要发现

  • 随访参与者与非参与者之间、3个参与研究组之间的母亲社会人口学、妊娠及新生儿特征总体无显著差异(所有P值≥.05)。
  • 阴道黄体酮200 mg/d、400 mg/d或200及400 mg/d暴露儿童在儿童行为量表6至18岁版问卷11项精神病理综合征量表上的均分与安慰剂暴露儿童无显著差异(所有P值≥.05)。
  • 儿童行为量表总均分在阴道黄体酮各组(200 mg/d组31.08±22.58、400 mg/d组37.48±28.59、200及400 mg/d组34.00±25.60)与安慰剂组(34.60±25.55)之间无显著差异(P分别为.38、.54、.87)。
  • 瑞文测验平均百分位在阴道黄体酮200 mg/d组(63.11±27.03)和400 mg/d组(60.40±31.51)略高于安慰剂组(59.40±30.64),但差异未达统计学显著(P分别为.44、.85)。

关键数值与推荐

  • 阴道黄体酮给药方案:200 mg/d或400 mg/d,自妊娠20周至34周或分娩(以先发生者为准)。
  • 儿童行为量表6至18岁版问卷11项精神病理综合征量表均分:各黄体酮暴露组与安慰剂组比较,所有P值≥.05。
  • 儿童行为量表总均分:200 mg/d组31.08±22.58、400 mg/d组37.48±28.59、200及400 mg/d组34.00±25.60、安慰剂组34.60±25.55(P分别为.38、.54、.87)。
  • 瑞文测验平均百分位:200 mg/d组63.11±27.03、400 mg/d组60.40±31.51、安慰剂组59.40±30.64(P分别为.44、.85)。

临床怎么用

  • 原文未据此给出推荐;结论为妊娠后半期每日200 mg或400 mg阴道黄体酮预防早产对双绒毛膜双胎6至9岁时精神病理及认知特征无影响。

局限性

  • 随访纳入104名母亲的206名儿童,占原随机对照试验纳入者的35.4%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current evidence indicates that administration of vaginal progesterone to women with a twin gestation and a short cervix reduces the risk of preterm birth occurring at early gestational ages and of neonatal morbidity and mortality. However, the potential long-term effects of prenatal administration of vaginal progesterone for preventing preterm birth on the psychopathological and cognitive profiles of twins remain unknown. OBJECTIVE: To evaluate the psychopathological and cognitive profiles at 6 to 9 years of age of surviving children born to mothers who participated in a randomized controlled trial that compared 2 different daily doses of vaginal progesterone (200 mg and 400 mg) to placebo to prevent preterm birth in dichorionic twin gestations. STUDY DESIGN: This is a follow-up study from a multicenter, double-blind, randomized controlled trial with 3 parallel groups (placebo, vaginal progesterone 200 mg/d, and vaginal progesterone 400 mg/d administered from 20 to 34 weeks of gestation or delivery, whichever came first; randomization ratio 1:1:1). The Child Behavior Checklist for ages 6 to 18 questionnaire and the Raven's colored progressive matrices test of nonverbal intelligence were applied to the participating mothers and their surviving children aged 6 to 9 years, respectively. The participant mothers, questionnaire collector, and database organizer were blinded to the intervention received in the original trial. The primary outcomes were behavioral, emotional, and social problems evaluated by the Child Behavior Checklist for ages 6 to 18 questionnaire, and the intelligence coefficient percentile evaluated by the Raven's colored progressive matrices test. Analyses were performed on an intention-to-treat basis using descriptive and analytical tests. P values <.05 were considered statistically significant. RESULTS: A total of 206 children born to 104 mothers (35.4% of those included in the original randomized controlled trial) were included in the study: 75 were exposed to vaginal progesterone 200 mg/d, 63 to vaginal progesterone 400 mg/d, and 68 to placebo. Overall, there were no significant differences in maternal sociodemographic, pregnancy, and neonatal characteristics between participants and nonparticipants in the follow-up study and between the 3 participating study groups (all P values ≥.05). The mean scores of the 11 psychopathological syndrome scales evaluated by the Child Behavior Checklist for ages 6 to 18 questionnaire among children exposed to vaginal progesterone 200 mg/d, 400 mg/d, or 200 and 400 mg/d were not significantly different to those among children exposed to placebo (all P values ≥.05). There were no significant differences in the mean total Child Behavior Checklist score between the vaginal progesterone groups (31.08±22.58 for the 200 mg/d group, 37.48±28.59 for the 400 mg/d group, and 34.00±25.60 for the 200 and 400 mg/d group) and the placebo group (34.60±25.55) (P=.38, .54, and .87, respectively). The mean percentiles of the Raven's test were slightly higher among children exposed to vaginal progesterone 200 mg/d (63.11±27.03) and 400 mg/d (60.40±31.51) than among those exposed to placebo (59.40±30.64), although these differences were not statistically significant (P=.44 and .85, respectively). CONCLUSION: Exposure to 200 or 400 mg/d of vaginal progesterone in the second half of pregnancy for preterm birth prevention had no effect on the psychopathological and cognitive profiles of dichorionic twins at 6 to 9 years of age.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Perales A, Aviño J, Diaz-Martinez A, et al. Prenatal exposure to vaginal progesterone for the prevention of preterm birth is not associated with abnormal psychopathological and cognitive profiles in dichorionic twins at 6 to 9 years of age: a follow-up study of a randomized controlled trial. Am J Obstet Gynecol. 2025. PMID: 40339952. doi:10.1016/j.ajog.2025.04.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。